Argent BioPharma draws another A$350K from its A$11M convertible facility
What's the deal? Argent BioPharma has drawn a further A$350,000 from its convertible securities facility, backed by US institutional investors managed by C/M Capital Partners. In return, the ASX-listed biopharma company (ticker RGT) will issue 385,000 new unquoted convertible notes with a face value of A$1.00 each.
Why now? The drawdown expands the total facility to a potential A$11 million and lifts Argent's cash reserves by up to A$350,000. It marks another quick tap of a structured funding line the company has come to rely on.
What's the endgame? Argent develops and commercialises healthcare and biotechnology products. Like many early and growth-stage biopharma firms, it leans on convertible instruments to fund its development pipeline while managing cash flow.
What could go wrong? The notes increase Argent's liability by their A$385,000 aggregate face value and could push shares on issue from 116,609,584 to 126,234,584 if converted at the floor price. That signals dilution risk for existing shareholders, even as short-term liquidity improves.
The company has provided a pro-forma balance sheet based on its December 31, 2025 audited accounts to show the impact of the new notes. The figures have not been independently audited but are meant to give investors clearer visibility into its capital structure.
The signal: By issuing a cleansing notice under section 708A of the Corporations Act, Argent ensures shares from converted notes can be on-sold to retail investors without extra disclosure. The move keeps the company compliant with Australian securities law and reflects a wider biotech pattern: turning to convertible notes and structured facilities to bridge the gap between R&D spending and commercial revenue.
Read more: TipRanks
Image credit: foteih
